ClinicalTrials.gg
CompletedNCT07934004DDTVSPTRUpdated Nov 12, 2026

Combined Effects of Transcutaneous Auricular Vagus Nerve Stimulation and Pelvic Floor Rehabilitation in Patients With Dyssynergic Defecation: A Randomized Controlled Trial

An interventional study of Biofeedback-Based Pelvic Floor Rehabilitation and Transcutaneous Auricular Vagus Nerve Stimulation (Active taVNS) in Dyssynergic Defecation, sponsored by Istanbul Bilgi University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Istanbul Bilgi University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Mar 2026, registered Nov 2026).
Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 72 studies in Constipation with a site in Turkey — 16 open to participants now, 21 under way, none of them phase 3. Constipation · Turkey.

Enrollment
48th of 57
32 · median 54
Started
2026
with 11 others
No phase
56 of 72
11 open now
Registered
72nd of 72
by date

Among the 72 studies in Constipation with a site in Turkey, this one is the 48th largest by enrollment of the 57 interventional ones that give a count, is one of 12 that started in 2026, is one of 56 with no phase, and was the 72nd registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

16 of the 72 studies in Constipation with a site in Turkey are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Constipation with a site in Turkey, or all of them as a file.
02

Study summary

Biofeedback-based pelvic floor rehabilitation is an established treatment approach for dyssynergic defecation (DD), aiming to restore appropriate muscle coordination during defecation. However, the potential role of autonomic nervous system regulation and stress responses in gastrointestinal function has encouraged the investigation of additional therapeutic approaches.

This randomized, sham-controlled clinical trial aims to evaluate the additional effects of transcutaneous auricular vagus nerve stimulation (taVNS) combined with biofeedback-based pelvic floor rehabilitation, compared with sham stimulation combined with the same rehabilitation program, on constipation symptoms, defecation function, pelvic floor muscle activity, autonomic regulation, psychological symptoms, and quality of life in individuals with dyssynergic defecation.

Read the detailed description

Dyssynergic defecation (DD) is a functional defecation disorder associated with chronic constipation and characterized by impaired coordination of the pelvic floor muscles and anal sphincter during defecation. Biofeedback-based pelvic floor rehabilitation is recommended as a first-line treatment approach for dyssynergic defecation. However, the relationship between autonomic nervous system regulation, psychological factors, and gastrointestinal function has encouraged the investigation of additional therapeutic interventions. Transcutaneous auricular vagus nerve stimulation (taVNS) is a noninvasive neuromodulation technique that may influence autonomic regulation.

This prospective, randomized, sham-controlled clinical trial enrolled 32 participants aged 18-65 years diagnosed with dyssynergic defecation in general surgery and gastroenterology clinics. Participants were allocated into two groups using computer-generated block randomization: an active taVNS group (n=16) and a sham stimulation group (n=16).

Both groups received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. In the intervention group, participants additionally received 30 minutes of transcutaneous auricular vagus nerve stimulation during each rehabilitation session. In the sham group, electrodes were placed at the same anatomical locations, but therapeutic electrical stimulation was not delivered.

Assessments were conducted before and after the treatment period. Constipation severity was evaluated using the Constipation Severity Instrument (CSI), colorectal symptoms using the Colorectal-Anal Distress Inventory-8 (CRADI-8), constipation-related quality of life using the Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL), and psychological symptoms using the Hospital Anxiety and Depression Scale (HADS). Bowel habits were recorded using the Bristol Stool Form Scale and a defecation diary. Pelvic floor muscle activity was assessed using a surface electromyography (EMG) biofeedback system, focusing on work average and rest average parameters. Cardiac autonomic regulation was assessed through heart rate variability (HRV) analysis, including RMSSD, SDNN, pNN50, LF Power, HF Power, and the LF/HF ratio.

The study aimed to evaluate the additional effects of active taVNS combined with biofeedback-based pelvic floor rehabilitation compared with sham stimulation on constipation severity, colorectal symptoms, bowel habits, pelvic floor muscle activity, constipation-related quality of life, psychological symptoms, and cardiac autonomic regulation in individuals with dyssynergic defecation.

03

Conditions studied

  • Dyssynergic Defecation

Browse trials for

Keywords

  • Dyssynergic Defecation
  • Biofeedback
  • Pelvic Floor Rehabilitation
  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
  • Heart Rate Variability (HRV)
  • Constipation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18-65 years. Diagnosis of dyssynergic defecation (DD). Ability to read and understand the study procedures. Provision of written to participate in the study.

Exclusion criteria

Exclusion Criteria:

Pregnancy or breastfeeding. Severe neurological disorders (e.g., multiple sclerosis or Parkinson's disease).

Presence of a cardiac pacemaker or other implanted electronic device. Uncontrolled hypertension or cardiac disorders. Diagnosis of severe anxiety disorder or depression. Use of medications that affect balance. Structural or metabolic disorders that may cause chronic constipation (e.g., Hirschsprung's disease).

Presence of an acute ear infection or wound. Previous treatment with pelvic floor rehabilitation or transcutaneous auricular vagus nerve stimulation (taVNS).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Active taVNS Group

    Participants in this group received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. In addition, 30 minutes of active transcutaneous auricular vagus nerve stimulation (taVNS) was administered during each session.

    Behavioral: Biofeedback-Based Pelvic Floor Rehabilitation · Device: Transcutaneous Auricular Vagus Nerve Stimulation (Active taVNS)

  • Sham comparator
    Sham taVNS Group

    Participants in this group received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. Sham taVNS was administered for 30 minutes during each session, with electrodes placed at the same anatomical locations as in the active group, but without therapeutic electrical stimulation.

    Behavioral: Biofeedback-Based Pelvic Floor Rehabilitation · Device: Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)

Interventions

  • BehavioralBiofeedback-Based Pelvic Floor Rehabilitation

    Participants received 16 sessions of biofeedback-based pelvic floor rehabilitation over a two-month period. The rehabilitation program included pelvic floor muscle awareness and relaxation training, coordination exercises between the abdominal and pelvic floor muscles, and education on appropriate defecation techniques. Surface electromyography (EMG) biofeedback was used to provide visual feedback on muscle activity and facilitate the learning of appropriate contraction and relaxation patterns. The intervention aimed to reduce inappropriate pelvic floor muscle contraction during defecation, improve muscle coordination, and promote effective bowel emptying.

  • DeviceTranscutaneous Auricular Vagus Nerve Stimulation (Active taVNS)

    Participants in the intervention group received active transcutaneous auricular vagus nerve stimulation (taVNS) in addition to biofeedback-based pelvic floor rehabilitation. Electrical stimulation was delivered through electrodes placed on the auricular region to target the auricular branch of the vagus nerve. Stimulation was administered for 30 minutes during each of the 16 rehabilitation sessions over a two-month period. The intervention aimed to modulate autonomic nervous system activity and investigate its potential additional effects on constipation symptoms, defecation function, psychological symptoms, and heart rate variability (HRV).

  • DeviceSham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)

    Participants in the sham group received biofeedback-based pelvic floor rehabilitation combined with sham transcutaneous auricular vagus nerve stimulation. Electrodes were placed at the same anatomical locations as in the active taVNS group, and the procedure was conducted for 30 minutes during each of the 16 rehabilitation sessions over a two-month period. However, therapeutic electrical stimulation was not delivered. The sham procedure was designed to be similar to the active intervention in appearance and duration to maintain participant blinding and allow evaluation of the additional effects of active taVNS.

06

What researchers measure

Primary outcomes

  1. Change in Constipation Severity Instrument (CSI) Total Score

    Constipation severity was assessed using the 16-item Constipation Severity Instrument (CSI), comprising three subscales: obstructive defecation (0-28 points), colonic inertia (0-29 points), and pain (0-16 points). The total score ranges from 0 to 73, with higher scores indicating greater constipation severity. Changes in total CSI scores from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.

    Time frame: Baseline and 2 months (post-intervention)

Secondary outcomes

  1. Change in Colorectal-Anal Distress Inventory-8 (CRADI-8) Score

    Colorectal and anal symptom distress was assessed using the eight-item Colorectal-Anal Distress Inventory (CRADI-8), a subscale of the Pelvic Floor Distress Inventory-20 (PFDI-20). Scores range from 0 to 100, with higher scores indicating greater symptom distress. Changes in scores from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.

    Time frame: Baseline and 2 months (post-intervention)

  2. Change in Patient Assessment of Constipation Quality of Life (PAC-QOL) Score

    Constipation-related quality of life was assessed using the 28-item Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire, comprising four domains: worries and concerns, physical discomfort, psychosocial discomfort, and satisfaction. Higher scores indicate a greater negative impact of constipation on quality of life. Changes from baseline to post-intervention were compared between the active taVNS and sham taVNS groups.

    Time frame: Baseline and 2 months (post-intervention)

  3. Change in Hospital Anxiety and Depression Scale - Anxiety (HADS-A) Score

    Anxiety symptoms were assessed using the seven-item anxiety subscale of the Hospital Anxiety and Depression Scale (HADS-A). Scores range from 0 to 21, with higher scores indicating greater anxiety symptoms. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  4. Change in Hospital Anxiety and Depression Scale - Depression (HADS-D) Score

    Depressive symptoms were assessed using the seven-item depression subscale of the Hospital Anxiety and Depression Scale (HADS-D). Scores range from 0 to 21, with higher scores indicating greater depressive symptoms. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  5. Change in Pelvic Floor Muscle EMG Work Average (µV)

    Pelvic floor muscle electrical activity during contraction was assessed using surface electromyography (EMG) with the NeuroTrac MyoPlus2 Pro device. Work Average was recorded in microvolts (µV) during repeated five-second contractions. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  6. Change in Pelvic Floor Muscle EMG Rest Average (µV)

    Pelvic floor muscle electrical activity during relaxation was assessed using surface electromyography (EMG) with the NeuroTrac MyoPlus2 Pro device. Rest Average was recorded in microvolts (µV) during repeated five-second relaxation periods. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  7. Change in Heart Rate Variability - RMSSD (ms)

    Heart rate variability was assessed using the Polar H10 chest strap and Elite HRV application. RMSSD, the root mean square of successive differences between normal-to-normal RR intervals, was measured in milliseconds (ms). Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  8. Change in Heart Rate Variability - pNN50 (%)

    Heart rate variability was assessed using the Polar H10 chest strap and Elite HRV application. pNN50 represents the percentage of successive normal-to-normal RR intervals differing by more than 50 milliseconds. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  9. Change in Heart Rate Variability - LF Power

    Low-frequency (LF) power was assessed through frequency-domain heart rate variability analysis using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  10. Change in Heart Rate Variability - HF Power

    High-frequency (HF) power was assessed through frequency-domain heart rate variability analysis using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  11. Change in Heart Rate Variability - LF/HF Ratio

    The ratio of low-frequency to high-frequency power (LF/HF) was calculated from heart rate variability measurements obtained using the Polar H10 chest strap and Elite HRV application. Changes from baseline to post-intervention were compared between groups.

    Time frame: Baseline and 2 months (post-intervention)

  12. Change in Weekly Bowel Movement Frequency

    Weekly bowel movement frequency was assessed using a defecation diary. The number of bowel movements per week was recorded at baseline and after the two-month intervention period. Changes in weekly bowel movement frequency were compared between the active taVNS and sham taVNS groups. Higher values indicate more frequent bowel movements.

    Time frame: Baseline and 2 months (post-intervention)

07

Study locations

1 site
  • EV
    Bahçelievler, Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Oct 2026, 7 months.

Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 7 months is below that.

Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2026
First posted
Nov 12, 2026
StartActual
Mar 15, 2026
Primary completionActual
Oct 15, 2026
CompletionActual
Oct 15, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934004
Lead sponsor
Istanbul Bilgi University
Responsible party
AYCAN ÇAKMAK REYHAN (Assistant Professor, Istanbul Bilgi University) — Principal investigator
First posted
Nov 12, 2026
Start date
Mar 15, 2026
Primary completion
Oct 15, 2026
Completion
Oct 15, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion